Insider Selling: Apogee Therapeutics, Inc. (NASDAQ:APGE) Insider Sells 3,520 Shares of Stock

Apogee Therapeutics, Inc. (NASDAQ:APGE - Get Free Report) insider Carl Dambkowski sold 3,520 shares of Apogee Therapeutics stock in a transaction on Wednesday, February 5th. The shares were sold at an average price of $40.69, for a total value of $143,228.80. Following the completion of the transaction, the insider now owns 252,623 shares in the company, valued at $10,279,229.87. The trade was a 1.37 % decrease in their position. The sale was disclosed in a legal filing with the SEC, which can be accessed through the SEC website.

Carl Dambkowski also recently made the following trade(s):

• On Thursday, January 2nd, Carl Dambkowski sold 4,085 shares of Apogee Therapeutics stock. The stock was sold at an average price of $46.94, for a total value of $191,749.90.
• On Wednesday, December 11th, Carl Dambkowski sold 4,540 shares of Apogee Therapeutics stock. The stock was sold at an average price of $48.76, for a total value of $221,370.40.
• On Wednesday, December 4th, Carl Dambkowski sold 6,665 shares of Apogee Therapeutics stock. The shares were sold at an average price of $46.07, for a total transaction of $307,056.55.

Apogee Therapeutics Stock Performance

Shares of NASDAQ APGE traded down $3.89 during midday trading on Tuesday, reaching $35.46. 633,966 shares of the company's stock were exchanged, compared to its average volume of 512,348. The stock has a market capitalization of $1.60 billion, a PE ratio of -14.69 and a beta of 2.18. Apogee Therapeutics, Inc. has a 52-week low of $33.14 and a 52-week high of $72.29. The business's fifty day moving average price is $44.11 and its two-hundred day moving average price is $48.45.

Apogee Therapeutics (NASDAQ:APGE - Get Free Report) last posted its quarterly earnings data on Tuesday, November 12th. The company reported ($0.86) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.73) by ($0.13). Analysts predict that Apogee Therapeutics, Inc. will post -3.09 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

Several research firms have recently issued reports on APGE. Canaccord Genuity Group started coverage on shares of Apogee Therapeutics in a research report on Monday, November 25th. They issued a "buy" rating and a $89.00 price objective for the company. Canaccord Genuity Group assumed coverage on Apogee Therapeutics in a research report on Monday, November 25th. They issued a "buy" rating and a $89.00 price objective on the stock. Guggenheim reaffirmed a "buy" rating on shares of Apogee Therapeutics in a research report on Monday. Finally, Wedbush raised their target price on Apogee Therapeutics from $87.00 to $90.00 and gave the company an "outperform" rating in a report on Monday, December 2nd. Seven equities research analysts have rated the stock with a buy rating, According to MarketBeat, Apogee Therapeutics has an average rating of "Buy" and a consensus price target of $89.71.

Institutional Trading of Apogee Therapeutics

Hedge funds and other institutional investors have recently made changes to their positions in the stock. Zurcher Kantonalbank Zurich Cantonalbank acquired a new position in Apogee Therapeutics during the 3rd quarter worth $71,000. Mirae Asset Global Investments Co. Ltd. lifted its position in shares of Apogee Therapeutics by 21.2% during the third quarter. Mirae Asset Global Investments Co. Ltd. now owns 1,628 shares of the company's stock worth $94,000 after purchasing an additional 285 shares during the last quarter. Wexford Capital LP acquired a new position in Apogee Therapeutics in the third quarter worth about $230,000. Aigen Investment Management LP bought a new stake in Apogee Therapeutics in the fourth quarter valued at about $216,000. Finally, Commonwealth Equity Services LLC acquired a new stake in Apogee Therapeutics during the fourth quarter valued at approximately $222,000. Institutional investors own 79.04% of the company's stock.

Apogee Therapeutics Company Profile

Apogee Therapeutics, Inc, through its subsidiary, operates as a biotechnology company that develops biologics for the treatment of atopic dermatitis (AD), asthma, chronic obstructive pulmonary disease (COPD), and related inflammatory and immunology indications. The company primarily develops APG777, a subcutaneous (SQ) extended half-life monoclonal antibody (mAb) for AD; and APG808, an SQ extended half-life mAb for COPD.